Genzyme Miss...

Alright, I admit my mistakes and was wrong on Amgen (Ticker: AMGN) and Genzyme (Ticker: GENZ). Genzyme reported today and missed pretty big on both the revenues and earnings per share. The company's revenues increased 16% to $730.8 million, but that was below analysts expectations of $749 million. The earnings per share came in as $0.59 per share vs. expectations of $0.63 per share. The Street punished the stock by sending it down 7.6% to $60.78. The company reiterated it’s guidance for the year so it's expecting much better numbers in the upcoming quarters. The stock will not do much until we see the Q2 results. So in the mean time, I’ll avoid Amgen and Genzyme, but will continue to pick up Genentech on weakness. Yeah, Genzyme is my largest position…